ILLINOIS TOOL WORKS INC — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ILLINOIS TOOL WORKS INC filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | $3.58B | Feb 15, 2019 |
| FY2018 | Sep 30, 2018 | $3.61B | Feb 15, 2019 |
| FY2018 | Jun 30, 2018 | $3.83B | Feb 15, 2019 |
| FY2018 | Mar 31, 2018 | $3.74B | Feb 15, 2019 |
| FY2018 | Dec 31, 2017 | $3.63B | Feb 15, 2019 |
| FY2018 | Sep 30, 2017 | $3.62B | Feb 15, 2019 |
| FY2018 | Jun 30, 2017 | $3.60B | Feb 15, 2019 |
| FY2018 | Mar 31, 2017 | $3.47B | Feb 15, 2019 |
| FY2018 | Dec 31, 2016 | $13.60B | Feb 15, 2019 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.04B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $15.90B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $16.11B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $15.93B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $14.46B | Feb 9, 2024 |
| FY2020 | Dec 31, 2020 | $3.48B | Feb 12, 2021 |
| FY2020 | Sep 30, 2020 | $3.31B | Feb 12, 2021 |
| FY2020 | Jun 30, 2020 | $2.56B | Feb 12, 2021 |
| FY2020 | Mar 31, 2020 | $3.23B | Feb 12, 2021 |
| FY2020 | Dec 31, 2019 | $3.47B | Feb 12, 2021 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $3.63B | Feb 15, 2018 |
| FY2017 | Sep 30, 2017 | $3.62B | Feb 15, 2018 |
| FY2017 | Jun 30, 2017 | $3.60B | Feb 15, 2018 |
| FY2017 | Mar 31, 2017 | $3.47B | Feb 15, 2018 |
| FY2017 | Dec 31, 2016 | $3.40B | Feb 15, 2018 |
| FY2017 | Sep 30, 2016 | $3.50B | Feb 15, 2018 |
| FY2017 | Jun 30, 2016 | $3.43B | Feb 15, 2018 |
| FY2017 | Mar 31, 2016 | $3.27B | Feb 15, 2018 |
| FY2016 | Dec 31, 2015 | $3.28B | Feb 10, 2017 |
| FY2016 | Sep 30, 2015 | $3.35B | Feb 10, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $4.22B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $4.26B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $4.04B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $3.79B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $3.48B | Feb 9, 2024 |
| FY2020 | Dec 31, 2020 | $883.00M | Feb 12, 2021 |
| FY2020 | Sep 30, 2020 | $789.00M | Feb 12, 2021 |
| FY2020 | Jun 30, 2020 | $449.00M | Feb 12, 2021 |
| FY2020 | Mar 31, 2020 | $761.00M | Feb 12, 2021 |
| FY2020 | Dec 31, 2019 | $824.00M | Feb 12, 2021 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $302.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $292.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $284.00M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $269.00M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $239.00M | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | $214.00M | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $221.00M | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $233.00M | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $225.00M | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $223.00M | Feb 15, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.13B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $3.28B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $3.54B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $2.35B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $2.56B | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | $2.81B | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $3.00B | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $2.81B | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $2.40B | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $2.30B | Feb 15, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $419.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $437.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $455.00M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $412.00M | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $296.00M | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | $236.00M | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $326.00M | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $364.00M | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $297.00M | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $273.00M | Feb 15, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $16.15B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $15.07B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $15.52B | Feb 14, 2025 |
| FY2024 | Dec 31, 2022 | $15.42B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $16.08B | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | $15.61B | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $15.07B | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $14.87B | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $16.78B | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $15.20B | Feb 15, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.10B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $4.84B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $4.91B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $4.86B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $4.97B | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | $4.69B | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $4.49B | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $4.63B | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $4.75B | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $4.56B | Feb 15, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $30.15B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $28.89B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $27.12B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $25.80B | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | $24.33B | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | $23.11B | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | $22.40B | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $21.22B | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $20.21B | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | $19.51B | Feb 15, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $851.00M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $948.00M | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $1.07B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $708.00M | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | $1.53B | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | $2.56B | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | $1.98B | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | $1.50B | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $3.09B | Feb 15, 2019 |
| FY2018 | Dec 31, 2016 | $2.47B | Feb 15, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.68B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $7.09B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $7.70B | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | $6.71B | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | $7.48B | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | $8.12B | Feb 11, 2022 |
| FY2019 | Dec 31, 2019 | $7.76B | Feb 14, 2020 |
| FY2019 | Dec 31, 2018 | $7.38B | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | $7.48B | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | $7.83B | Feb 15, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 10 | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | 11 | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | 9 | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | 9 | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | 8 | Feb 9, 2024 |
| FY2020 | Dec 31, 2020 | 2 | Feb 12, 2021 |
| FY2020 | Sep 30, 2020 | 1 | Feb 12, 2021 |
| FY2020 | Jun 30, 2020 | 1 | Feb 12, 2021 |
| FY2020 | Mar 31, 2020 | 1 | Feb 12, 2021 |
| FY2020 | Dec 31, 2019 | 2 | Feb 12, 2021 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 10 | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | 11 | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | 9 | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | 9 | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | 8 | Feb 9, 2024 |
| FY2020 | Dec 31, 2020 | 2 | Feb 12, 2021 |
| FY2020 | Sep 30, 2020 | 1 | Feb 12, 2021 |
| FY2020 | Jun 30, 2020 | 1 | Feb 12, 2021 |
| FY2020 | Mar 31, 2020 | 1 | Feb 12, 2021 |
| FY2020 | Dec 31, 2019 | 1 | Feb 12, 2021 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 288.60M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | 294.00M | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | 299.30M | Feb 14, 2025 |
| FY2023 | Dec 31, 2022 | 305.00M | Feb 9, 2024 |
| FY2022 | Dec 31, 2021 | 312.90M | Feb 10, 2023 |
| FY2021 | Dec 31, 2020 | 316.70M | Feb 11, 2022 |
| FY2020 | Dec 31, 2019 | 319.80M | Feb 12, 2021 |
| FY2019 | Dec 31, 2018 | 328.10M | Feb 14, 2020 |
| FY2018 | Dec 31, 2017 | 341.50M | Feb 15, 2019 |
| FY2017 | Dec 31, 2016 | 346.90M | Feb 15, 2018 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.79B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.70B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $1.62B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $1.54B | Feb 14, 2025 |
| FY2023 | Dec 31, 2021 | $1.46B | Feb 9, 2024 |
| FY2022 | Dec 31, 2020 | $1.38B | Feb 10, 2023 |
| FY2021 | Dec 31, 2019 | $1.32B | Feb 11, 2022 |
| FY2020 | Dec 31, 2018 | $1.12B | Feb 12, 2021 |
| FY2019 | Dec 31, 2017 | $941.00M | Feb 14, 2020 |
| FY2018 | Dec 31, 2016 | $821.00M | Feb 15, 2019 |